Patents by Inventor Bingliang Chen

Bingliang Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240026019
    Abstract: The present invention relates to an anti-TNFR2 antibody, a preparation method therefor, a composition thereof, and use thereof. The present invention also provides a method for treating a TNFR2-associated disease and/or disorder, such as cancer.
    Type: Application
    Filed: January 28, 2022
    Publication date: January 25, 2024
    Inventors: Yiming LI, Bingliang CHEN, Hua JING
  • Publication number: 20230272079
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: February 9, 2023
    Publication date: August 31, 2023
    Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.
    Inventors: Alan J. KORMAN, Mohan SRINIVASAN, Changyu WANG, Mark J. SELBY, Bingliang CHEN, Josephine M. CARDARELLI, Haichun HUANG
  • Patent number: 11655296
    Abstract: The present invention relates to novel antibodies and antibody fragments thereof that specifically bind to integrin-associated proteins (IAP, or CD47), and a composition comprising the antibodies or the antibody fragments. The present invention also relates to a nucleic acid encoding the antibodies or the antibody fragments thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the present invention also relates to therapeutic and diagnostic use of the antibodies and the antibody fragments.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: May 23, 2023
    Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Dandan Liu, Weifeng Huang, Bingliang Chen, Junjian Liu
  • Patent number: 11512131
    Abstract: The invention relates to a novel antibody and an antibody fragment that specifically bind to PD-L1 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and a related use. Furthermore, the invention relates to a therapeutic and diagnostic use of these antibodies and antibody fragments. Particularly, the invention relates to a combined treatment of these antibodies and antibody fragments with other therapies.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: November 29, 2022
    Assignee: Innovent Biologies (Suzhou) Co., Ltd.
    Inventors: Xiaoniu Miao, Huajing Hu, Junjian Liu, Bingliang Chen, Li Li
  • Patent number: 11498972
    Abstract: The present invention relates to an antibody and antibody fragment that specifically binds to OX40 and to a composition comprising said antibody or antibody fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or antibody fragment thereof and a host cell comprising the same, and to a related use thereof. In addition, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: November 15, 2022
    Assignee: Innovent Biologics (Suzhou) Co., Ltd.
    Inventors: Andy Tsun, Hemanta Baruah, Xiaolin Liu, Cheng Chen, Junjian Liu, Bingliang Chen, Weifeng Huang
  • Publication number: 20220112284
    Abstract: The present invention provides a novel, artificially designed antibody molecule comprising: a polypeptide chain of formula (I): VH-CH1-Fc-X-VHH; and a polypeptide chain of formula (II): VL-CL; wherein: the VH represents a heavy chain variable region; the CH represents a heavy chain constant region; the Fc comprises CH2, CH3, and optionally CH4; the CH1, the CH2, the CH3 and the CH4 represent domains 1, 2, 3 and 4, respectively, of the heavy chain constant region; the X may be absent, or represents a linker such as a flexible linker when present; the VHH represents a single-domain antigen-binding site such as a single-domain antibody; the VL represents a light chain variable region; the CL represents a light chain constant region; optionally, a hinge region is present between the CH1 and the Fc.
    Type: Application
    Filed: January 23, 2020
    Publication date: April 14, 2022
    Inventors: Haiqing NI, Bingliang CHEN, Junjian LIU
  • Patent number: 11292836
    Abstract: The present invention is directed to a novel antibody against CD47 and the antibody fragments thereof and a composition comprising the antibody or antibody fragments thereof. The present invention relates further to a nucleic acid encoding the antibodies or antibody fragments thereof and host cells comprise the same, as well as the relevant use of the same. In addition, the present invention is also directed to the use of these antibodies and antibody fragments in the therapy and diagnosis.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: April 5, 2022
    Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Andy Tsun, Dandan Liu, Bingliang Chen, Junjian Liu
  • Publication number: 20210363267
    Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.
    Type: Application
    Filed: July 28, 2021
    Publication date: November 25, 2021
    Inventors: Josephine M. CARDARELLI, Daniel E. LOPES de MENEZES, Paul D. PONATH, Bingliang CHEN, Chin PAN
  • Patent number: 11104739
    Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 31, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Josephine M. Cardarelli, Daniel E. Lopes de Menezes, Paul D. Ponath, Bingliang Chen, Chin Pan
  • Publication number: 20200377593
    Abstract: The present invention relates to novel antibodies and antibody fragments thereof that specifically bind to integrin-associated proteins (IAP, or CD47), and a composition comprising the antibodies or the antibody fragments. The present invention also relates to a nucleic acid encoding the antibodies or the antibody fragments thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the present invention also relates to therapeutic and diagnostic use of the antibodies and the antibody fragments.
    Type: Application
    Filed: March 26, 2019
    Publication date: December 3, 2020
    Inventors: Dandan LIU, Weifeng HUANG, Bingliang CHEN, Junjian LIU
  • Publication number: 20200332009
    Abstract: The invention relates to a novel antibody and an antibody fragment that specifically bind to PD-L1 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and a related use. Furthermore, the invention relates to a therapeutic and diagnostic use of these antibodies and antibody fragments. Particularly, the invention relates to a combined treatment of these antibodies and antibody fragments with other therapies.
    Type: Application
    Filed: December 27, 2018
    Publication date: October 22, 2020
    Inventors: Xiaoniu Miao, Huajing Hu, Junjian Liu, Bingliang Chen, Li Li
  • Publication number: 20200181259
    Abstract: The present invention is directed to a novel antibody against CD47 and the antibody fragments thereof and a composition comprising the antibody or antibody fragments thereof. The present invention relates further to a nucleic acid encoding the antibodies or antibody fragments thereof and host cells comprise the same, as well as the relevant use of the same. In addition, the present invention is also directed to the use of these antibodies and antibody fragments in the therapy and diagnosis.
    Type: Application
    Filed: August 28, 2018
    Publication date: June 11, 2020
    Inventors: Andy TSUN, Dandan LIU, Bingliang CHEN, Junjian LIU
  • Publication number: 20200138945
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: October 11, 2019
    Publication date: May 7, 2020
    Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Publication number: 20200140562
    Abstract: The present invention relates to a novel antibody and antibody fragment that specifically binds to OX40 and to a composition comprising said antibody or antibody fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or antibody fragment thereof and a host cell comprising the same, and to a related use thereof. In addition, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.
    Type: Application
    Filed: March 23, 2018
    Publication date: May 7, 2020
    Inventors: Andy Tsun, Hemanta Baruah, Xiaolin Liu, Cheng Chen, Junjian Liu, Bingliang Chen, Weifeng Huang
  • Patent number: 10441655
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 15, 2019
    Assignees: ONO PHARMACEUTICAL CO., LTD., E.R. SQUIBB & SONS, L.L.C.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Publication number: 20190119395
    Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.
    Type: Application
    Filed: April 14, 2017
    Publication date: April 25, 2019
    Inventors: Josephine M. CARDARELLI, Daniel E. LOPES de MENEZES, Paul D. PONATH, Bingliang CHEN, Chin PAN
  • Publication number: 20170088615
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: October 7, 2016
    Publication date: March 30, 2017
    Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.
    Inventors: Alan J. KORMAN, Mohan SRINIVASAN, Changyu WANG, Mark J. SELBY, Bingliang CHEN, Josephine M. CARDARELLI, Haichun HUANG
  • Patent number: 9492539
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: November 15, 2016
    Assignees: Ono Pharmaceutical Co., Ltd., E.R. Squibb & Sons, L.L.C.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Patent number: 9492540
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: November 15, 2016
    Assignees: Ono Pharmaceutical Co., Ltd., E.R. Squibb & Sons, L.L.C.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Patent number: 9387247
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: July 12, 2016
    Assignees: Ono Pharmaceutical Co., Ltd., E.R. Squibb & Sons L.L.C.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang